SCHEMBL304424

SCHEMBL304424

CC(C)C1=C(C(C)C)C(=O)OC1=O

nearest known ligand 0.32

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
CDC25A P30304 2/20 0.32
CDC25B P30305 2/20 0.32
ALOX15 P16050 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
TSHR P16473 2/20 0.30
ALDH1A1 P00352 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL304605 0.83
SCHEMBL304331 0.77 CDC25A (0.31) CDC25ACDC25B
SCHEMBL15201154 0.75
SCHEMBL3413343 0.70 CDC25A (0.37) CDC25ACDC25B
SCHEMBL16201653 0.60 CDC25A (0.32) CDC25ACDC25B
SCHEMBL12851540 0.60 TOP2A (0.31) TDP1ALDH1A1
SCHEMBL16201624 0.60 CDC25A (0.32) CDC25ACDC25B
SCHEMBL22654547 0.60 ALOX15 (0.37) ALOX15TDP1TSHRALDH1A1
SCHEMBL5587224 0.58 CDC25A (0.36) CDC25ACDC25B
SCHEMBL5587123 0.58 CES2 (0.39) CDC25ACDC25BALOX15TDP1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113024724-B Method for continuous polymerization of cracked fractions 清华大学 2023-03-28 CN disclosed
CN-113136239-B Utilization method of ethylene cracking tar and application of compound containing carbon-carbon double bond 清华大学 2022-05-13 CN disclosed
CN-113563152-A Method for treating C five fraction and use of olefinic bond-containing compound 清华大学 2021-10-29 CN disclosed
CN-113136239-A Utilization method of ethylene cracking tar and application of compound containing carbon-carbon double bond 清华大学 2021-07-20 CN disclosed
CN-113122315-A Method for treating ethylene tar and use of carbonyl compound containing olefinic bond 清华大学 2021-07-16 CN disclosed
CN-113024724-A Method for continuous polymerization of cracked fractions 清华大学 2021-06-25 CN disclosed
CN-112852482-A Method for treating cracked fractions and use of compounds containing olefinic bonds 清华大学 2021-05-28 CN disclosed
US-20160151322-A1 METALLO-B-LACTAMASE INHIBITORS MEIJI SEIKA KAISHA (JP) 2016-06-02 US disclosed
US-20160151322-A1 METALLO-B-LACTAMASE INHIBITORS MEIJI SEIKA KAISHA (JP) 2016-06-02 US disclosed
US-20160151322-A1 METALLO-B-LACTAMASE INHIBITORS MEIJI SEIKA KAISHA (JP) 2016-06-02 US disclosed
EP-1941873-A1 METALLO-BETA-LACTAMASE INHIBITOR MEIJI SEIKA KAISHA LTD. (JP) 2008-07-09 EP disclosed
US-20080090825-A1 Metallo-beta-lactamase inhibitors MEIJI SEIKA KAISHA, LTD. (JP) 2008-04-17 US disclosed
US-20080090825-A1 Metallo-beta-lactamase inhibitors MEIJI SEIKA KAISHA, LTD. (JP) 2008-04-17 US disclosed
US-20080090825-A1 Metallo-beta-lactamase inhibitors MEIJI SEIKA KAISHA, LTD. (JP) 2008-04-17 US disclosed
US-5145916-A Heat resistant adhesive for aircraft and spacecraft UBE INDUSTRIES, LTD. (JP) 1992-09-08 US disclosed
EP-0395020-A2 Terminal-modified imide oligomer composition UBE INDUSTRIES, LTD. (JP) 1990-10-31 EP disclosed
US-4963645-A UNSATURATED END GROUPS UBE INDUSTRIES, LTD. (JP) 1990-10-16 US disclosed
US-4921745-A Honeycomb structure of aromatic polyimide UBE INDUSTRIES, LTD. (JP) 1990-05-01 US disclosed
EP-0304913-A2 Terminal-modified imide oligomer and solution composition of the same UBE INDUSTRIES, LTD. (JP) 1989-03-01 EP disclosed
US-4375974-A OLEFIN POLYMER-UNSATURATED ANHYDRIDE-POLYAMINE REACTION PRODUCT INSTITUT FRANCAIS DU PETROLE (FR) 1983-03-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080090825-A1 Metallo-beta-lactamase inhibitors ME1, MGAM, GAA CDC25A 989/4885CDC25B 1424/4885ALOX15 535/4885
US-20160151322-A1 METALLO-B-LACTAMASE INHIBITORS ME1, MGAM, MANBA CDC25A 854/4885CDC25B 928/4885ALOX15 487/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.